Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man Max 99 years
Sanofi Pasteur
Update Il y a 4 ans
Immunogenicity of the Investigational Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip in the Elderly
To demonstrate that the intradermal ID investigational vaccine induces a better immunogenicity than the intramuscular IM reference vaccine in terms of seroprotection rate after the first vaccinati...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Immunogenicity of the Purified Vero Rabies Vaccine – Serum Free in Comparison with the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults
To demonstrate that VRVg (PR1) is at least as immunogenic as the reference vaccine, Verorab (PR2), in terms of seroconversion rate at D42, i.e. 14 days after the last vaccination of primary vaccinatio...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur Incorporated
Update Il y a 4 ans
Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Booster Vaccination with Infanrix® hexa when Both Vaccines Are Co-Administered with Prevenar® to Toddlers 11-18 Months of Age
To evaluate the safety of PEDIACEL® booster dose by comparing the fever rates between PEDIACEL® and Infanrix® hexa vaccines when both are co-administered with Prevenar® to toddlers at 11-18 months of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route)
To check the compliance, in terms of immunogenicity, of the inactivated, split-virion influenza vaccine Northern Hemisphere 2006-2007 formulation with the requirements of the European Medicines Agency...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
An open-label, multicentre study to evaluate the immunogenicity and safety of one dose of a diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (REPEVAX®) followed by 2 doses of a diphtheria, tetanus and poliomyelitis vaccine (REVAXIS®) in subjects of 40 years of age or older without a previous diphtheria and tetanus-containing booster within the last 20 years
To demonstrate that 3 doses of a vaccine containing Td-IPV valences administered in a 0, 1 and 6-month schedule induce an acceptable immune response in terms of seroprotection rates (SPR) against diph...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD S.N.C
Update Il y a 4 ans
A double blind comparative and randomised study in healthy adults of the safety, tolerability, and immunogenicity of PNEUMOVAX®II formulated with either all new process polysaccharides or all current process polysaccharides
To compare the post-vaccination geometric mean titres (GMTs) of antibody to pneumococcal serotypes 3 and 8 in recipients of PNEUMOVAX®II formulated with all new process polysaccharides to the same ant...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-aventis U.S. Inc
Update Il y a 4 ans
A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis
To investigate the tolerability and safety of a 7 mg and a 14 mg dose of teriflunomide administered once daily for 24 weeks, compared with placebo in subjects with multiple sclerosis who are concurren...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur Limited
Update Il y a 4 ans
A Follow-Up To Study Td506: Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) Compared to Tetanus and Diphtheria Toxoids Adsorbed (Td) in Adolescents and Adults 11 – 64 Years of Age
Long-term follow-up study to describe the profile of antibody levels after booster vaccination with Tdap vaccine or Td vaccine at 1-month, 1-, 3-, and 5-years postvaccination and Tdap only at 10 years...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Sanofi-Aventis recherche & de`veloppement
Update Il y a 4 ans
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, 24-week study followed by an extension assessing the efficacy and safety of AVE0010 in two titration regimens on top of metformin in patients with type 2 diabetes not adequately controlled with metformin
The primary objective of this study is to assess the effects of AVE0010 as an add-on treatment to metformin on glycemic control using a two-step dose titration regimen in comparison to placebo in term...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur Limited
Update Il y a 4 ans
One-, Three-, Five- and Ten-Year Data on the Long-Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adolescents 11–14 Years of Age
To describe the antibody levels for tetanus, diphtheria and pertussis at 1 year, 3 years, 5 years and 10 years after vaccination with Tdap Vaccine.
Country
None
organs
None
Specialty
None
More information
Previous
2
3
4
5
6
7
8
9
10
11
Next